Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 8:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ramipril (ACE inhibitor) Clear all
Completed Phase 2 Interventional

Effects of Angiotensin-Converting Enzyme Inhibitor (Ramipril) Therapy on Blood Vessel Inflammation

NCT00005928
View directory record Official record
Conditions
Atherosclerosis, Coronary Disease, Vasculitis
Interventions
Ramipril
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 28, 2026, 8:15 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Renin-angiotensin-aldosterone System (RAAS), Inflammation, and Post-Operative Atrial Fibrillation (AF)

NCT00141778
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Placebo, Ramipril, Spironolactone
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Sep 28, 2026, 8:15 PM EDT
Completed Phase 2 Interventional Results available

Study of Inflammation and Oxidative Stress in Persons Undergoing Dialysis

NCT00732069
View directory record Official record
Conditions
End Stage Renal Failure on Dialysis, Complication of Hemodialysis
Interventions
Placebo, Ramipril, Valsartan
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 1, 2013 · Synced Sep 28, 2026, 8:15 PM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 28, 2026, 8:15 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Impact of Diabetes on Left Ventricular Remodeling

NCT01052272
View directory record Official record
Conditions
Diabetes
Interventions
Ramipril, Candesartan cilexetil, Allopurinol
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 16, 2012 · Synced Sep 28, 2026, 8:15 PM EDT
Completed Phase 3 Interventional

Ramipril and Hydrochlorothiazide Alone and in Combination for the Treatment of Essential Hypertension

NCT00355589
View directory record Official record
Conditions
Hypertension, Blood Pressure, High
Interventions
Ramipril and hydrochlorothiazide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
60
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2012 · Synced Sep 28, 2026, 8:15 PM EDT
Terminated Not applicable Interventional Results available

ACE-Inhibitor Effects on Total Hip and Knee Arthroplasty Patients

NCT01867047
View directory record Official record
Conditions
Adverse Effects of Angiotensin-converting-enzyme Inhibitors, Hypotension
Interventions
ACE-I Cessation group, ACE-I Continuation group
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Sep 28, 2026, 8:15 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3

NCT00878969
View directory record Official record
Conditions
Oxidative Stress, Endothelial Dysfunction
Interventions
valsartan (ARB), ramipril (ACE inhibitor), Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 14, 2016 · Synced Sep 28, 2026, 8:15 PM EDT
Completed Phase 4 Interventional

Treatment of Pediatric Hypertension With Altace Trial

NCT00044265
View directory record Official record
Conditions
Hypertension
Interventions
ramipril
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 16 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
30
States / cities
Birmingham, Alabama • Los Angeles, California • Augusta, Georgia + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Sep 28, 2026, 8:15 PM EDT
Completed Phase 4 Interventional Results available

Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery

NCT01669434
View directory record Official record
Conditions
Hypotension on Induction
Interventions
ACEI continuation, ACEI omission
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 90 Years
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 24, 2023 · Synced Sep 28, 2026, 8:15 PM EDT
Completed Phase 3 Interventional Results available

Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI

NCT02924727
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
LCZ696 (sacubitril/valsartan), Ramipril, Placebo of LCZ696, Placebo of ramipril, Valsartan, Placebo of valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5,669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
81
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 28, 2026, 8:15 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Ramipril for the Treatment of Oligospermia

NCT01856361
View directory record Official record
Conditions
Oligospermia, Teratospermia, Asthenozoospermia, Male Infertility
Interventions
Ramipril, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Sep 28, 2026, 8:15 PM EDT
Completed No phase listed Observational

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

NCT04467931
View directory record Official record
Conditions
Hypertension, COVID
Interventions
ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
22,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Sep 28, 2026, 8:15 PM EDT
Terminated Phase 3 Interventional Results available

PREVENTKD (Prevent Risks by Early interVEntion at Nighttime in Type 1 Diabetes for Kidney Disease)

NCT00729365
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Ramipril, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
13 Years to 50 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Gainesville, Florida • Chicago, Illinois • Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 16, 2015 · Synced Sep 28, 2026, 8:15 PM EDT
Terminated Phase 2 Interventional Results available

Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors

NCT01234922
View directory record Official record
Conditions
Hypertension, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
lisinopril, losartan potassium, laboratory biomarker analysis, benazepril hydrochloride, ramipril
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Sep 28, 2026, 8:15 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome

NCT01432106
View directory record Official record
Conditions
Hypertension, Metabolic Syndrome
Interventions
Aliskerin/Valsartan and Rampiril
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 17, 2013 · Synced Sep 28, 2026, 8:15 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.

NCT00153101
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Telmisartan, Combination of Telmisartan and Ramipril, Ramipril
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
55 Years and older
Enrollment
31,546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
100
States / cities
Athens, Alabama • Birmingham, Alabama • Phoenix, Arizona + 84 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 28, 2026, 8:15 PM EDT
Completed Not applicable Interventional Results available

Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure

NCT02130687
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Hypertension
Interventions
Placebo, Sitagliptin, Aprepitant, Mixed Meal Test (MMT)
Drug · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Sep 28, 2026, 8:15 PM EDT